Press Release

Veracyte to Participate in Upcoming Investor Conferences

May 23, 2023
PDF Version

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 23, 2023-- Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences:

  • William Blair 43rd Annual Growth Stock Conference – Chicago, IL
    Presentation on June 6th at 9:40 a.m. Eastern Time
  • Goldman Sachs 44th Annual Global Healthcare Conference – Dana Point, CA
    Fireside Chat on June 13th at 6:20 p.m. Eastern Time

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay of the webcasts will be available for 90 days following the conclusion of the live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Investors:
Shayla Gorman
Director, Investor Relations
investors@veracyte.com
619-393-1545

Media:
Tracy Morris
Vice President of Global Corporate Communications
tracy.morris@veracyte.com
650-380-4413

Source: Veracyte, Inc.